Patient-derived ER+ breast cancer xenografts treated with tamoxifen in combination with the Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-737 [37], an analogue of ABT-263, displayed decreased tumor growth and increased tumor cell death [45]. This evidence concerns the gene BCL2L1 and breast cancer.